Document:

Collaboration Agreement Among Transword Pharmaceuticals and Toray Trading Corp.

			
	 	  	Exhibit 10.16
	 	  	Portions redacted
	 	  	* Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

  
 COLLABORATION
AGREEMENT 
  
 THIS AGREEMENT is made as of April 30, 2001, 

 
 BETWEEN: 
  
 Transworld Pharmaceuticals Corporation Inc., a company having offices at Sassoon House, Shirley Street, Nassau, New
Providence, Bahamas, and Toray Trading Corp. a Cyprus company 
  
 (“TPh / Toray”) 
  
 AND: 
  
 Dragon Pharmaceuticals Inc., a corporation having an office at 543
Granville St., Vancouver, BC. Canada V6C lX8 
  
 (“Dragon”) 
  
 WHEREAS: 
  
 (A) Transworld Pharmaceuticals Corporation, together with Toray, having control and ownership
of certain intellectual property, to whit: methods of formulation of purified bulk recombinant Human erythropoietin (rHu EPO) with recombinant Hyaluronic Acid (rHA), for the achievement of a novel slow-release formulation of rHu EPO.

  
 (B) TPh / Toray has agreed to grant certain rights to Dragon to manufacture
and sell the Product in a specified market, and to manufacture the product on a fee-for-service basis for sale to TPh / Toray; 
  
 THIS AGREEMENT WITNESSES that in consideration of $1 paid and other consideration given, by each party to each other party, the receipt and sufficiency of which
each party acknowledges, the parties severally AGREE as follows: 
  
 PART l 
  
 DEFINITIONS AND INTERPRETATION

  
 Definitions 
  
 1.1 In this Agreement, except as otherwise expressly provided or as the context otherwise
requires: 
  
 (a) Affiliate of a party means a corporation
or entity that, directly or indirectly, controls, is under common control with or is controlled by the specified party; 
  

 1 

 (b) current GMP means current good manufacturing practices as determined by the World Health
Organization; 
  
 (c) Indication means the use of the
Product to treat a particular condition as described in Schedule A; 
  
 (d) Marketing Approval has the meaning set out in §2.9; 
  
 (e) Product means the formulation of rHu EPO and rHA achieving a novel slow release formulation 
  
 (f) Purchase Orders has the meaning set out in §4.5 
  

Interpretation 
  
 1.2 In this Agreement, except as otherwise expressly provided or as the context otherwise requires, 
  
 (a) “this Agreement” means this agreement as from time to time supplemented or amended by one or more agreements entered into pursuant to the
applicable provisions of this Agreement, 
  
 (b) a reference to a
Part is to a Part of this Agreement, and the symbol § followed by a number or some combination of numbers and letters refers to the section, paragraph, subparagraph, clause or subclause of this Agreement so designated, 
  
 (c) headings are solely for convenience of reference and are not intended to
be complete or accurate descriptions of content or to be guides to interpretation of this Agreement or any part of it, 
  
 (d) the word “including”, when following a general statement or term, is not to be construed as limiting the general statement or term to any
specific item or matter set forth or to similar items or matters. but rather as permitting the general statement or term to refer also to all other items or matters that could reasonably fall within is broadest possible scope, 
  
 (e) an accounting term not otherwise defined herein has the meaning assigned
to it, and every calculation to be made hereunder is to be made, in accordance with accounting principles generally accepted in the United States applied on a consistent basis, 
  
 (f) a reference to currency means United States currency, 
  
 (g) a reference to a statute includes all regulations made thereunder, all amendments to the statute or regulations in force
from time to time, and every statute or regulation that supplements or supersedes such statute or regulations, 
  
 (h) a reference to an entity includes any successor to that entity, 
  
 (i) a word importing the masculine gender includes the feminine and neuter, a word in the singular includes the plural, a
word importing a corporate entity includes an individual, and vice versa, 
  

 2 

 (j) and a reference to “approval”, “authorization” or “consent” means
written approval, authorization or consent. 
  
 PART 2

  
 GRANT OF LICENSE 
  
 License 
  
 2.1 Subject to the terms of this Agreement, TPh / Toray hereby grants to Dragon an exclusive license to manufacture and sell the Products in
the Market Area for treatment of the Indications. Additionally, Dragon is to be the sole manufacturer of the product for markets both within its territory, as well as for territories in which TPh / Toray market the product. 
  
 2.2 Nothing in this Agreement confers on Dragon any interest, licence or right in respect of
Products other than as set out herein, and the Products will remain the exclusive property of TPh / Toray and its Affiliates. Sales outside of the Market Area are prohibited, unless granted in writing to Dragon by TPh / Toray. New Drug Licenses and
production permits for the product within China are to be owned by Dragon. 
  
 2.3
Dragon will forthwith disclose to TPh / Toray every improvement to or further development of the Products, including the results of any research, testing or clinical trials conducted by or on behalf of Dragon. The results of such research, testing,
trials and improvements will be immediately disclosed to TPh / Toray and will be jointly owned by TPh / Toray and Dragon, without any obligation of Dragon, with respect to the ownership or use of such information or the payment of any compensation.

  
 Dragon’s Regulatory Obligations 
  
 2.4 Dragon will be responsible for obtaining, at its expense, all registrations from
applicable regulatory authorities in order to permit the manufacture and sale of the product in the Market Area (the “Marketing Approval”). In particular, Dragon will 
  
 (a) Complete any and all actions required to register the product with the State Drug Administration of the People’s
Republic of China in order to obtain a new drug license and manufacturing permit for the product. 
  
 2.5 TPh / Toray will use reasonable efforts to assist Dragon in obtaining the new drug license and manufacturing permit, including providing to Dragon 
  
 (a) Results of any and all technical research, to include full results of pre-clinical, phase I and phase II human
studies, and 
  
 (b) TPh / Toray will work to achieve optimum
formulation methods using purified bulk EPO provided at no cost by Dragon, and will provide documentation of same. 
  
 (c) Additionally, TPh / Toray will provide hands-on technical assistance to Dragon affiliates in China and North America during the initial period of
collaboration. 
  
 (d) Costs to be borne by either side during
the development phase of this collaboration are as described in Schedule A. 
  

 3 

 2.6 All registrations made in order to obtain the Marketing Approval in China will be made by Dragon on its own behalf
and in its own name. 
  
 Sublicenses 
  
 2.7 Dragon may not grant sublicenses to sell the Products in the Market Area, except as
authorised in writing by TPh / Toray. 
  
 PART 3 

 
 MARKETING 
  
 Marketing Plan 
  
 3.1 Dragon, TPh /Toray and their Affiliates will jointly develop a marketing plan (the “Marketing Plan”) for the sale of
the products in the Market Area, which will include targets for reasonable minimum Product sales by Dragon. The marketing plan will be prepared by September 1 of each year and will cover the following 12-month period from January 1 to December 31.
The Marketing Plan will be reviewed quarterly by representatives of Dragon and TPh / Toray. 
  
 Branding 
  
 3.2 Dragon and TPh / Toray
will jointly determine a name under which the Products will be sold in the Market Area. At Dragon’s option, the name “Transworld Pharma Corp.” and any related trademarks will be included in, or linked and used with, the name selected.
TPh / Toray and Dragon will jointly own the brand name developed. 
  
 Market
Area Packaging 
  
 3.3 Dragon will work with TPh / Toray to develop
distinctive packaging materials suitable to the Market Area. All packaging will be subject to the approval of TPh / Toray and will include, at the option of TPh / Toray, such trademark or logos of TPh / Toray or its Affiliates as determined by TPh /
Toray. Dragon will be responsible for the costs of all packaging. 
  
 PART 4 
  
 PRICING, ORDERS AND PAYMENT

  
 Price 
  
 4.1 TPh / Toray will receive from Dragon royalties from net sales of product at rates set
out in Schedule A, such rates to be in effect until December 31 of each year. 
  
 4.2 Notwithstanding any change in the royalty rates set out in Schedule A, no price change will effect the price of any Products for which a Purchase Order has been received and accepted by Dragon. 
  
 4.3 Dragon’s price to TPh / Toray for the finished product manufactured by Dragon is set
our in Schedule A. 
  

 4 

 Resale Prices 
  
 4.4 Subject to all applicable laws and the approval of TPh / Toray, which will not be unreasonably withheld, Dragon will determine the prices at which the Products will
be sold in the Market Area. In reviewing the resale price for the Products, TPh / Toray and Dragon will take into account considerations of consumer affordability and maintaining appropriate price advantages over competitors. 
  
 Delivery Times 
  
 4.5 Dragon will promptly fill all purchase Orders received from TPh / Toray in accordance with the terms of each Purchase Order and will
ensure, unless a longer delivery time is specified in a Purchase Order, a 60-day delivery time for each such Purchase Order. If Dragon is able to deliver the Products in a shorter period of time than specified in the Purchase Order, it will notify
TPh / Toray of such earlier delivery date. 
  
 4.6 Notwithstanding §4.7, if
Dragon for any reason can not meet the delivery times in a Purchase Order, it will notify TPh / Toray of the expected delivery date when it confirms the Purchase Order under §4.6. Upon receipt of Dragon’s notice of the expected delivery
date, TPh / Toray may, on notice delivered to Dragon within five business days of Dragon’s receipt of TPh / Toray’s confirmation of the Purchase Order, withdraw the Purchase Order. If the Purchase Order is not withdrawn, the delivery times
in §4.7 will be deemed to be amended to the time set out in Dragon’s confirmation of the Purchase Order. 
  
 Payment 
  
 4.7 TPh / Toray will make full payment to Dragon for Products shipped to it on a date after the date of shipment agreed on a case by case basis provided that before the expiry of the payment period, Dragon has
received from TPh / Toray the following documents: 
  
 (a)
Dragon’s detailed invoice; 
  
 (b) customs’ invoice;

  
 (c) air waybill; 
  
 (d) packing list; and 
  
 (e) pharmaceutical certificate of analysis, quality assurance and quality
control documents and batch certificates. 
  
 Letter of Credit 

 
 4.8 TPh / Toray will, at the request of Dragon, at any time during the term of this
Agreement, provide a standby letter of credit to Dragon, which letter of credit may be drawn by Dragon upon default by TPh / Toray of payment in collection with any Products as provided in §4.7. Notwithstanding any other provision of this
Agreement, if it has requested a letter of credit Dragon will not be obligated to manufacture or deliver any Product until it has received the letter of credit. 
  

4.9 The value of the standby letter of credit need not exceed the value of the Purchase Order for which Dragon has requested the letter of credit. 
  

 5 

 Audit Right 
  
 4.10 Dragon will keep clear and accurate books and records of all sales of Products in the Market Area. Up to twice a year, at the request and expense of TPh / Toray, and
upon at least five days prior written notice, Dragon will permit TPh / Toray to review the books and records during regular business hours. 
  
 Additional Procedures 
  
 4.11 The parties recognize that additional procedures related to the purchase and shipment of Products may be necessary from time to time during the term of this Agreement and each will cooperate with the other to
formulate and implement new policies and procedures. 
  
 PART 5

  
 MANUFACTURING 
  
 Specifications 
  
 5.1 Dragon will produce, or will arrange for the production of, all Products to its best technical standards and in accordance with current
GMP in effect at the time of manufacture. 
  
 Shipping 
  
 5.2 Dragon will ensure that each shipment conforms to the Purchase Order and all Products
will be packaged and shipped in accordance with recognized standards for guaranteeing maintenance of the “cold” chain from the Products’ manufacturing facility to Dragon’s facility, through a mutually agreed upon air courier
service. To permit the proper tracking of a Product, the air waybill number will be transmitted to Dragon as soon as practicable after shipment of the Product. 
  

Storage and Inspection 
  
 5.3 TPh / Toray will promptly store all Products immediately upon receipt in a storage facility described in §2.12(b) and will, as soon as practicable after receipt
of any Product, inspect the shipment and advise Dragon of conformity with the Purchase Order. 
  
 Testing of Product 
  
 5.4 TPh / Toray may
arrange for: the Product to be tested at an independent third party facility including government ministry-operated laboratories in Sweden or Portugal, to determine whether the efficacy or purity of the Product is within manufacturing specifications
as provided for in the Marketing Approval. TPh / Toray will promptly notify Dragon of such test results once received. 
  
 5.5 If the testing conducted under §5.4 determines that the Product fails to meet the standards of efficacy or purity required under the terms of the Marketing
Approval, TPh / Toray will be entitled to receive, at the option of Dragon, a refund of the purchase price as specified in the Purchase Order or a replacement shipment of the Product. Notwithstanding the foregoing, Dragon may, before providing a
refund or replacement Product, conduct testing at an independent third party facility of the Product shipment. If the results of Dragon’s testing indicate that the Product does meet the standards set out in the Marketing Approval, TPh / Toray
and Dragon will use good 

  

 6 

 
faith efforts to resolve the discrepancy in the test results and make a determination as to the suitability of the shipment for sale. 
  
 PART 6 
  
 CONFIDENTIALITY AND NON-COMPETITION 
  
 Confidentiality 
  
 6.1 In order to protect all confidential or proprietary information that may be shared between the parties during the term of this Agreement, concurrent with, or as soon
as practicable after, the execution of this Agreement, the parties will enter into a non-disclosure agreement. 
  
 6.2 The non-disclosure agreement referred to in §6.1 will, with the necessary changes, be substantially in the form of the agreement dated October 19th, 2000 between TPh and Dragon. 
  
 Non-Competition 
  
 6.3 During the term of this Agreement, and for a period of three years thereafter, Dragon will not, directly or indirectly, 
  
 (a) in sole proprietorship, 
  
 (b) in any partnership, 
  
 (c) as the owner then more than 10% of the shares of any class of any
corporation engaged in the manufacture, sale or distribution of the Product, or 
  
 (d) in a business which competes with the TPh / Toray or its Affiliates or partners, 
  
 engage in or carry on the business of manufacturing, distributing, marketing or selling, the Product in and outside of the Market Area, including seeking to, either
directly or indirectly, obtain a licence or any other right or authority from any party to manufacture, distribute, market or sell a product which competes with the Product. 
  
 6.4 Dragon agrees and acknowledges that all the restrictions in this Agreement are reasonable for the protection of the legitimate business
interests and proprietary rights of TPh / Toray and its Affiliates and hereby waives all defences to the strict enforcement thereof. 
  
 PART 7 
  
 DISPUTE RESOLUTION 
  
 Disputes 
  
 7.1 If at any time there is a dispute among the
parties with respect to any matter relating to this Agreement, any party that wishes the issue to be considered further will give notice to the other of that it requires the dispute to be decided under the terms of this Agreement. 
  

 7 

 Referral to Senior Officers 
  
 7.2 If a notice is given under §7.1, a senior officer designated by each party will undertake discussions for the purpose of settling
the dispute. A decision reached by these officers and communicated in writing to the parties will be determinative of the dispute and will be binding on each party. 
  
 Arbitration 
  
 7.3 If no decision is reached under §7.2 within 30 days of the dispute being sent for consideration, either party may, by notice to the other party given at any time
before a decision is rendered under §7.2, submit the dispute for determination by a single arbitrator acting under the Rules of the British Columbia Commercial Arbitration Centre. 
  
 7.4 If the parties can not agree on a single arbitrator, the arbitrator will be appointed by the British Columbia International Commercial
Arbitration Centre. 
  
 7.5 The arbitration will take place in Vancouver, British
Columbia and will be administered by the British Columbia International Arbitration Centre and conducted in accordance with the procedures of the Centre. 
  
 PART 8 
  
 TERM AND TERMINATION 
  
 Term 
  
 8.1 This Agreement will be in effect for a 10 year
period from the date of signing and will be renewed automatically for successive three years terms unless otherwise terminated in accordance with the terms hereof (the “Term”). 
  
 Termination by Either Party 
  
 8.2 Either party may terminate this Agreement 
  
 (a) upon notice given at least 180 days before the end of the current Term, such termination to come into effect at the end of that Term, or 

 
 (b) immediately upon written notice if the other party 
  

	 	(i)	is in breach or violates any of the terms and conditions of or fails to perform any of its obligations under this Agreement and, after receiving notice from the other party, does
not cure such default within 60 days, or 

  

	 	(ii)	becomes insolvent, bankrupt, makes an assignment for the benefit of its creditors or has a receiver, receiver/manager, trustee or liquidator appointed in respect of its business or
its assets. 

  
 Termination by TPh / Toray: 
  
 8.3 Notwithstanding any other provision of this Agreement, TPh / Toray may terminate this
Agreement immediately upon written notice to Dragon if 
  

 8 

 (a) TPh / Toray and Dragon have not agreed to a revised pricing schedule as provided for in §4.1,

  
 (b) TPh / Toray determines, acting reasonably, that Dragon
has failed to satisfy any material provision of the current Marketing Plan, including a failure to meet any minimum purchase volume specified in the Marketing Plan, or; 
  
 (c) there is a breach of the non-disclosure agreement executed under §6.l. 
  
 Loss of Exclusivity 
  
 8.4 If TPh / Toray has the right to terminate the Agreement under §8.3, it may by notice to Dragon make the license granted under
§2.1 non-exclusive. The exercising of this right does not affect the ability of TPh / Toray to terminate this Agreement under §8.3 on a further occurrence of the matters set out in that section. 
  
 Liabilities 
  
 8.5 Upon termination of this Agreement, Dragon will be required to complete any and all existing Purchase Orders as at the date of
termination and Dragon will be required to receive and pay for all Products shipped in connection with such Purchase Orders. 
  
 PART 9 
  
 LIABILITIES AND INDEMNIFICATION 
  
 Limitation of Liability 
  
 9.1 TPh /
Toray will not be liable to Dragon or any of its Affiliates for any incidental, special, or consequential damages resulting from exercise of the rights granted herein or the use of the Product. The maximum amount of any liability of TPh / Toray to
Dragon for damages will be the amount of the Purchase Order in respect of the Product delivered which caused, or resulted in the allegation of, damages. 
  
 Indemnification 
  
 9.2 Dragon will indemnity, hold harmless, and defend TPh / Toray and its Affiliates, its officers, employees, and agents against any and all claims, suits, losses, damage, costs, fees, and expenses resulting from or
arising out of exercise of the rights granted under this Agreement and the sale of the Product. This indemnification will include, but will not be limited to, any product liability. 
  
 Insurance 
  
 9.3 Dragon, at its sole cost and expense, will insure its activities in connection with the work under this Agreement and obtain, keep in force, and maintain insurance or
an equivalent program of self insurance. 
  
 Notice of Claim 
  
 9.4 TPh / Toray will promptly notify Dragon in writing of any claim or suit brought against
TPh / Toray in respect of which Dragon intends to invoke the provisions of this Part. 
  

 9 

 Dragon will keep TPh / Toray informed on a current basis of its defense of any claims pursuant to this Part. 

 
 PART 10 
  
 GENERAL PROVISIONS 
  
 Entire Agreement 
  
 10.1 This Agreement constitutes the entire agreement between the parties and supersedes every previous agreement, communication,
negotiation, representation or understanding, whether oral or written, expressed or implied, between the parties with respect to the subject matter of this Agreement. 
  
 10.2 No director, officer, employee or agent of any party has any authority to make any representation or commitment not contained in this
Agreement and each party has executed this Agreement without reliance upon any such representation or commitment. 
  
 Force Majeure 
  
 10.3 No party will be liable for its failure to perform any of its obligations under this Agreement as a result of Acts of God (including all natural disasters), strikes, lockouts, civil disturbances, government or
court ordered interruptions or delays, acts of war and riots, but that either party to this Agreement may elect to terminate it upon three months written notice to the other if force majeure cannot or is not remedied within three months after its
occurrence. 
  
 Severability 
  
 10.4 If any provision of this Agreement is at any time unenforceable or invalid for any
reason it will be severable from the remainder of this Agreement and this Agreement will be construed as though such provision was not contained herein and the remainder will continue in full force and effect and be construed as if this Agreement
had been executed without the invalid or unenforceable provision. 
  
 Amendments 
  
 10.5 This Agreement may not be amended except in
writing signed by both parties. 
  
 Assignment 
  
 10.6 Neither party will be entitled to assign this Agreement without the written consent of
the other party, which consent may be unreasonably withheld. Notwithstanding the foregoing, TPh / Toray may assign this Agreement to an Affiliate. 
  
 Governing Law 
  
 10.7 This Agreement is and will be deemed to have been made in Province of British Columbia, for all purposes will be governed exclusively by and construed and enforced in accordance with the laws prevailing in the
British Columbia, and the rights and remedies of the parties will be determined in accordance with those laws. 
  

 10 

 Attornment 
  
 10.8 Each of the parties irrevocably attorns to the jurisdiction of the courts of the British Columbia and all courts having appellate jurisdiction thereover. 

 
 Notice 
  
 10.9 To be effective, a notice, request, demand or direction (each for the purposes of this provision a. “notice”) to be given
pursuant to this Agreement by one party to another party must be in writing and must be 
  
 (a) delivered by hand or by mail, or 
  
 (b) received by telecopier transmission or other similar from of written communication by electronic means. 
  
 in each case addressed as applicable as follows; 
  
 If to TPh / Toray at: 
  
 Rua Americo Durao 12, 6.DR. 1900 Lisbon, Portugal 
  
 Telecopier: +35121 847 1346 
  
 Attention: Dr. J. Transmontano. 
  
 with a copy to such other offices of TPh / Toray as may be specified by TPh / Toray to Dragon: 
  
 If to Dragon at: 
  
 1200, 543 Granville Street 
  
 Vancouver. BC, Canada V6C 1X8 
  
 Attention: Dr. Longbin Liu 
  
 Fax: ++1-604-669 4243 
  
 or to such other address or fax number as is specified by the addressee by notice to the
other party. 
  
 10.10 A notice delivered or sent in accordance with §10.9
will be deemed to be given and received 
  
 (a) at 8.00 a.m. on
the day of delivery or receipt at the place of delivery or receipt if that day is a Business Day at that place and the delivery or receipt is before that time on that day. 
  
 (b) at the time of delivery or receipt if received on or after 8.00 a.m. and before 4.00 p.m. at the place of delivery or
receipt on a day that is a Business Day at that place, and 
  
 (c) at 8.00 a.m. at the place of deliver or receipt on the next day that is a Business Day at that place, if delivered or received on a day that is not a Business Day at that place or at or after 4.00 p.m. at that place. 
  

 11 

 No Partnership 
  
 10.11 Nothing in this Agreement will constitute, by any means, a partnership between the parties. 
  
 Binding Effect 
  
 10.12 This Agreement will enure to the benefit of and be binding upon the respective successors and permitted assigns of the parties. 
  
 Further Assurances 
  
 10.13 Each party will, at such party’s own expense and without expense to the other party, execute and deliver such further agreements
and other documents and do such further acts and things as the other party reasonably requests to evidence, carry out or give full force and effect to the intent of this Agreement. 
  
 Counterparts 
  
 10.14 This Agreement may be executed in any number of counterparts with the same effect as if all parties to this Agreement had signed the same document, and all
counterparts will be construed together and constitute one and the same instrument. 
  
 IN WITNESS WHEREOF this Agreement was executed by the parties as of the day and year first above written. 
  

			
	TPh / Toray Inc.
		
	Per:	 	/s/    DR. JOAO
TRANSMONTANO        
	 	 	Dr. Joao Transmontano

  

			
		
	Per:	 	/s/    DR. BO G. DANIELSON
        
	 	 	Dr. Bo G. Danielson

  

			
	Dragon Pharmaceuticals, Inc.
		
	Per:	 	/s/    DR. LONGBIN
LIU        
	 	 	Dr. Longbin Liu

  

 12 

			
	Witnessed for Dragon Pharmaceuticals Inc. by:
		
	Per:	 	/s/    ROBERT K. WALSH        
	 	 	Robert K. Walsh

  

			
	Witnessed for TPh/Toray by:
		
	Per:	 	/s/    DR. JABOUR DE
ALVARENGA        
	 	 	Dr. Jabour de Alvarenga

  

 13 

 SCHEDULE A 
  

Products, Indications and Pricing 
  

			
		
	 Slow Release Formulation Net Sales
	  	 Royalty percentage - In effect until December 31, 2002

		
	 -All indications for product as approved by me State Drug Administration of the People’s Republic of China.
	  	 5% of net sales for Chinese Domestic Sales
 7% of net sales for remainder of market area

  
 Slow release formulation price to
TPh / Toray 
  

			
	 Per pre-filled injector/syringe
	 	 Dragon’s reasonable manufacturing cost* + US $ * * *

  

	*	Manufacturing cost comprises materials, depreciation on equipment, labour as mutually agreed prior to the launch of the product in the People’s Republic of China; Dragon’s
reference price per 1000IU of purified bulk EPO is understood to be USD $* * *. 

  
 Market Area 
  
 The People’s Republic
of China, the ASEAN member nations, Taiwan, Korea, and Japan 
  
 Costs

  

			
		
	 Purified bulk erythropoietin to Dr. Danielson
	  	Dragon
		
	 Cost of technology (know-how) transfer to Dragon
	  	TPh / Toray
		
	 Cost of travel & lodging, TPh / Toray key personnel to Nanjing, China. US DOS rates
	  	Dragon
		
	 Cost of Travel & Lodging, Dragon personnel to Upsalla, Sweden. US DOS rates
	  	TPh / Toray
		
	 Cost of any & all materials used for formulation during China-side development
	  	Dragon
		
	 Cost of registration in China to include phase II-III clinical studies
	  	Dragon

  
 * * * CONFIDENTIAL
MATERIAL REDACTED AND SEPARATELY FILED WITH 
 THE COMMISSION. 
  

 14Agent Agreement Among Allwin Biotrade, Jiangso Wuzhong Industry

					
	 	 	 	 	 Exhibit 10.17
 Portions redacted
 * Certain information on this page has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.

  
 Agent Agreement

  
 THIS AGREEMENT is made as of March 12, 2004 in Suzhou, China

  
 AMONG: 
  
 Allwin Biotrade, Inc., a corporation organized under the laws of British Virgin Islands with an office at East Asia
Chambers, P.O. Box 901, Road Town, Tortola, British Virgin Islands 
  
 (“Allwin Biotrade” Or “Agent”) 
  
 AND:

  
 Jiangsu Wuzhong Industry Co. Ltd., a corporation
Organized under the laws of the People’s Republic of China with an office at 338, East Baodai Road, Wuzhong District, Suzhou, People’s Republic of China. 
  
 (“Wuzhong”) 
  
 AND: 
  
 Jiangsu Wuzhong Industry Co. Ltd. Suzhou Zhongkai Bio-Pharmaceuticals Plant, a corporation organized under the laws of the People’s Republic of China with an office at 5, ChengHu Road, Wuzhong Economic Zone of
Development, SuZhou, People’s Republic of China. 
  
 (“Zhongkai”) 
  
 (“Wuzhong” and
“Zhongkai” are collectively hereinafter as “Licensors”) 
  
 (Allwin Biotrade are collectively hereinafter as “Agent”) 
  
 Each party is referred hereinafter as a “Party”, or “collectively as “Parties”) 
  
 WHEREAS: 
  

	 	A.	Licensor owns certain proprietary rights and license to use, sell or market a cytokine commonly know as Recombinant Human Granulocyte Colony Stimulating Factor (“rhG-CSF”
or “Product”) in People’s Republic of China (“PRC”) 

  

	 	B.	Agent possesses the expertise and experience in working with its Licensees internationally to register and market certain biotech products outside of China.

  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 1 

	 	C.	Licensor and Agent had signed a Letter of Intent on October 17, 2003 to confirm the Parties’ intention to enter into an agreement under which Agent would be the exclusive agent
to market Licensors’ rhG-CSF and other agreed upon products for all indications in certain countries and territories outside of China. 

  

THIS AGREEMENT WITNESSES that in consideration of $1 paid and other consideration given, by each party to each other party, the, receipt and sufficiency of
which each party acknowledges, the parties severally AGREE as follows: 
  
 Article 1. DEFINITIONS AND INTERPRETATION 
  
 1.1 In this
Agreement, except as otherwise expressly provided or as the context otherwise requires: 
  

	 	1.1.1 	“Product” means purified, quality-controlled Recombinant Human Granulocyte Colony Stimulating Factor, in bulk or finished dosages manufactured by Licensors;

  

	 	1.1.2 	“Affiliate” of a party means a corporation or entity that, directly or indirectly, controls, is under common control with or is controlled by the specified party;

  

	 	I.1.3 	“Arrival Airport” means the closest international airport to the shipping address specified in each Purchase Order. 

  

	 	1.1.4 	“FOB” shall have the meaning set forth in the International Chamber of Commerce document, “Incoterms 2000”. 

  

	 	1.1.5 	“Current GMP” means current good manufacturing practices as determined by the World Health Organization; 

  

	 	1.1.6	  “Departure Airport” means any of the major airports in the People’s Republic of China, including but not limited to airports in Beijing, Shanghai and Nanjing;

  

	 	1.1.7	  “Drug Master File” or “DMFI” means any and all information, process, techniques and data in Allwin Biotrade’s possession relating to the Product as
far as required to obtain Product Approval. 

  

	 	1.1.8	  “Market Area” means the territory or territories described in Schedule B; 

  

	 	1.1.9 	“Indication” means the use of the Product to treat a particular condition as described in Schedule B; 

  

	 	1.1.10 	“Marketing Plan” has the meaning set out in §3.1; 

  

	 	1.1.11 	“Parties” means both of the parties hereto collectively; and “Party,” depending upon context, shall mean either of them. 

  

	 	1.1.12 	“Registration Dossiers” means any and all information, processes, techniques, and data in Agent’s possession relating to the Finished Products as far as required to
obtain Product Approval. 

  

	 	1.1.13 	“Licensee” means any entity to which Agent grants sub-licenses of the Product under Agent’s rights specified in this Agreement. 

  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 2 

 1.2 In this Agreement, except as otherwise expressly provided or as the context otherwise requires, 
  

	 	1.2.1 	“this Agreement” means this agreement as from time to time supplemented or amended by one or more agreements entered into pursuant to the applicable provisions of this
Agreement, 

  

	 	1.2.2 	a reference to a Part is to a Part of this Agreement, and the symbol § followed by a number or some combination of numbers and letters refers to the section, paragraph,
subparagraph, clause or sub-clause of this Agreement so designated, 

  

	 	1.2.3 	headings are solely for convenience or reference and are not intended to be complete or accurate descriptions of content or to be guides to interpretation of this Agreement or any
part of it, 

  

	 	1.2.4 	the word “including”, when following a general statement or term, is not to be construed as limiting the general statement or term to any specific item or matter set forth
or to similar items or matters, but rather as permitting the general statement or term to refer also to all other items or matters that could reasonably fall within its broadest possible scope, 

  

	 	1.2.5 	an accounting term not otherwise defined herein has the meaning assigned to it, 

  

	 	1.2.6 	a reference to a statute includes all regulations made there-under, all amendments to the statute or regulations in force from time to time, and every statute or regulation that
supplements or supersedes such statute or regulations, 

  

	 	1.2.7	  a reference to an entity includes any successor to that entity, 

  

	 	1.2.8	  a word importing the masculine gender includes the feminine and neuter, a word in the singular includes the plural, a word importing a corporate entity includes an
individual, and vice versa  ,and 

  

	 	1.2.9	  a reference to “approval”, “authorization” or “consent” means written approval, authorization or consent. 

  
 Article 2. GRANT OF LICENSE 
  
 License 
  
 2.1 Subject to the terms of this Agreement, Licensors hereby appoint Agent to be the exclusive agent and distributor to market the Product
and Finished Product from Licensors in the Market Area as specified in Schedule B. To clarify further, in such Market Area described in Schedule B, Licensors shall not appoint any other agents or distributors, or grant any licensing or sub-licensing
rights of Products or Finished Products, or sell the Product or Finished Products directly or indirectly in the Market Area without the Agent. Meanwhile, Agent is not permitted to own an agent right or to distribute Recombinant Human Granulocyte.

  
 Colony Stimulating Factor for any other rhG-CSF manufacturers in China

  
 2.2 [Omitted Intentionally] 
  
 2.3 Nothing in this Agreement confers on Agent any interest, license or right in respect of
Product, other than as set out herein, and the Product will remain the exclusive property of the Licensors. 

  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 3 

 
Sales of the Product outside of the Market Area are prohibited unless agreed by Licensors and Agent will have no manufacturing rights of the Product.

  
 Agent’s Regulatory Obligations 
  
 2.4 Agent will be responsible for marketing and arranging licensing agreement with any
potential customers or Licensees to enable the Sale of the Product in the Marker Area. In particular, Agent will 
  

	 	2.4.1 	Initiate and engage in discussion and negotiate with any potential customers or Licensees to enter into licensing agreements to obtain registration and to sell and market the
Product in the Market Area. 

  

	 	2.4.2 	Assist Licensors, at Licensors’ own expense as specified in Schedule D, in meeting the documentation requirements in the Market Area to enable the Licensees to submit the
appropriate documentation to all applicable regulatory authorities in the Market Area. 

  

	 	2.4.3 	Liaise with Licensees and follow up on the registration process to make sure the Licensees will use all reasonable efforts to receive the: product approval in the Market Area in the
shortest possible time. 

  

	 	2.4.4 	Assist Licensors in obtaining quotes and estimates from contract service organizations in the United States of America and the European Union to undertake the testing to be
performed. 

  

	 	2.4.5 	Assist, if necessary, Licensors to liaise with the United States Department of Agriculture to obtain permits for Licensors to export the tested articles to a contract service
organization based in the United States. 

  
 2.5 Licensors will use
their best efforts together with Agent and Licensees to generate documentation in obtaining the Product Approval, including providing to Agent and Licensees 
  

	 	2.5.1 	the open part of the Drug Master File (“DMF”): Product will be described in a DMF of which Agent and Licensees wilt receive the open part and Licensors will supply the
closed part of the DMF directly to the applicable regulatory authorities of the Market Area. To clarify further, Agent or Licensees may not have access to the closed part of the DMF. 

  

	 	2.5.2 	any necessary information concerning the Product in the case of any question from the applicable regulatory authorities in the Market Area 

  

	 	2.5.3 	reasonable amounts of the Product, at the cost of Licensors, necessary for Agent or Licensees to conduct such research or clinical testing required to be completed in order to
obtain the Product Approval. 

  

	 	2.5.4 	access to the production facility, upon reasonable notice from the Agent, for the audit by applicable regulatory authorities and/or Licensees of the Market Area.

  
 Notwithstanding the foregoing, nothing will obligate Licensors
or any of its Affiliates to conduct any research activities or clinical trials in order for Agent or Licensees to obtain the Product Approval except that Licensors agree to perform at its own expense; (i) biosafety testing and characterization of
its e.coli cell line master cell bank; (ii) biosafety testing and characterization of end-or-passage cells (cells at the limit of in vitro life), (iii) bioburden testing of samples of at least three batches of raw supernatant and (iv) validation of
viral clearance in the downstream purification process. 
  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 4 

 Licensor shall be responsible for completing all of the validations, verifications and characteristics required for a
regulatory approval for rhG-CSF; Licensor shall be responsible for compliance to international pharmaceutical-biotechnological manufacturing GMP guidelines. 
  
 Sublicenses 
  
 2.6 Agent has sublicensing right to grant sublicenses granted under this Agreement to appoint other entities as Licensees for the purpose of selling and marketing the
Product within the Market Area. Agent should provide a copy of all sublicensing agreements signed between Agent and Licenses to Licensor within 15 days of signing of such agreements provided that such disclosure is not in violation of
the confidentiality agreed between Agent and Licensees. 
  
 Article 3.
MARKETING 
  
 Marketing Plan 
  
 3.1 Agent and Licensors will jointly develop a marketing plan (the “Marketing
Plan”) for the sale of the Product in the Market Area. The initial Marketing Plan, which covers the following l2 Month period, will be prepared within 120 days after signing of this Agreement and an update of such Marketing Plan with a rolling
l2-month forecast will be done every three months thereafter. The Marketing Plan will be reviewed quarterly by representatives of Agent and Licensors. 
  
 Article 4. PRICING, ORDERS AND PAYMENT 
  
 “See Schedule A” 
  
 4.1 Notwithstanding any change in the Product pricing set out in Schedule A, no price change will affect the price of any Product for which a purchase Order has been
issued and accepted. 
  
 4.2 All Product pricing set out in Schedule A are on a
FOB basis. The Arrival Airport will be specified in each Purchase Order. 
  
 4.3
Prices for Product are exclusive of customs fees and exercise and sales taxes in the importing country, and other taxes in the importing country in the nature of a sales tax, now existing or hereinafter imposed by national authorities
or those of any political subdivision thereof upon the sale of Product by Licensors to Agent. In the event any such fee or tax is imposed on, or assessed against, Licensors as a result of the sale and delivery of Product hereunder, Licensors shall
separately itemize such fees and taxes on the applicable invoices and Agent shall pay the appropriately invoiced amount within 60 days after receiving such invoices from Licensor. 
  
 Purchase Orders 
  
 4.4 Agent will prepare purchase orders (“Purchase Orders”) for all Product and each such order will specify the quantity of Product and any other information
that either party considers necessary. Purchase Orders cannot be amended without the consent of Licensors. 
  
 4.5 Licensors will acknowledge receipt of all Purchase Orders by a facsimile/e-mail sent within five (5) business days after receipt of the Purchase Order. 
  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 5 

 Delivery Times 
  
 4.6 Licensors will promptly fill all Purchase Orders received from Agent in accordance with the terms of each Purchase Order. If Licensors are able to deliver the Product
in a shorter period of time than specified in the Purchase Order, it will notify Agent of such earlier delivery date. 
  
 4.7 Notwithstanding §4.8, if Licensors for any reason can not meet the delivery times in a Purchase Order, it will notify Agent of the expected delivery date when it
confirms the Purchase Order under §4.7. Upon receipt of Licensor’s notice of the expected delivery date, Agent may, on notice delivered to Licensors within five (5) business days of Agent’ receipt of Licensor’s confirmation of
the Purchase Order, withdraw the Purchase Order. If the Purchase Order is not withdrawn, the delivery times in §4.8 will be deemed to be amended to the time set out in Licensors confirmation of the Purchase Order. 
  
 Payment 
  
 4.8 Within the first year of business operation (1 year from the date of first purchase order), the payment by Agent will be made by Letter
of Credit (L/C) at 60 days after shipment. 
  
 4.9 Other means of payment
could be discussed after that period. 
  
 Title and Risk 
  
 4.10 All Product pricing is on a FOB basis. Title to the Product and risk of toss or
damage shall pass to the Licensees when such Product is delivered onto the carrier at the Departure Airport. 
  
 Audit Right 
  
 4.11 Licensors will keep
clear and accurate books; and records of all sales of Finished Products in the Market Area. Up to twice a year, at the request and expense of Agents, and upon at least five days prior written notice, Licensors will permit Agent to review the books
and sales records of the Market Area during regular business hours. 
  
 Additional Procedures 
  
 4.12 The parties recognize that
additional procedures related to the purchase and shipment of Product may be necessary from time to time during the term of this Agreement and each will cooperate with the other to formulate and implement new policies and procedures. 
  
 Article 5. MANUFACTURING 
  
 Specifications 
  
 5.1 Licensor will produce all Product conforming to specifications laid down in Schedule B and in accordance with current GMPs in effect at
the time of manufacturing. All changes planned for the production of the product will have to be announced to Agent before implementation. 
  
 Shipping 
  
 5.2 Licensors will ensure that each shipment conforms to the Purchase Order and all Product will be packaged and shipped to the Arrival Airport as specified in each Purchase Order in accordance with the requirement
for maintenance at 2°C -8°C cold chain during shipment. To permit the proper tracking of the Product, the air waybill number will be transmitted to Agent as soon as practicable after shipment of the Product. 
  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 6 

 Testing of Product 
  
 5.3 Agent, through Licensees or itself may arrange for the Product to be tested at Agent’s laboratory or at an independent third party facility to determine whether
the efficacy or purity of the Product is within manufacturing specifications as provided for in the Product Approval. Agent will promptly notify Licensors of such test results once received. 
  
 5.4 Licensors or its Affiliates will provide the standard testing method of the Product to
Agent. 
  
 5.5 If the testing conducted under §5.4 determines that the
Product fails to meet the standards of efficacy or purity required under the terms of the Product Approval, Agent will be entitled to receive, at the Agent’s choice, a refund of the purchase price as specified in the Purchase Order or a
replacement shipment of the Product. Notwithstanding the foregoing, Licensors may, before providing a refund or replacement Product, conduct testing at an independent third party facility in the Market Area of the Product shipment. If the result of
Licensors’s testing indicates that the Product does meet the standards set out in the Product Approval, Licensors and Agent will use good faith efforts to resolve the discrepancy in the test results and make a determination as to the
suitability of the shipment for sale. 
  
 Article 6. CONFIDENTIALITY AND
NON-COMPETITION 
  
 Confidentiality 
  
 6.1 During the term of the Agreement, and for a period of one (1) years following the
expiration or earlier termination hereof, each Party shall exercise reasonable care to maintain in confidence all information of the other Party disclosed by the other Party and identified as, or acknowledged to be, confidential (“Confidential
Information”), and shall not use, disclose or grant the use of Confidential Information except on a need-to-know basis to those directors, officers, employees and permitted assignees, to the extent such disclosure is reasonably necessary in
connection with such Party’s activities as provided in the Agreement. Prior to disclosure, each Party hereto shall obtain the written agreement of any such Person, who is not otherwise bound by fiduciary obligations to such Party to hold in
confidence and not make use of the Confidential Information for any purpose other than those permitted by the Agreement. Each Party shall notify the other promptly upon discovery of any unauthorized use or disclosure of the other Party’s
Confidential Information. 
  
 Permitted Disclosures 
  
 6.2 The non-use and non-disclosure obligations contained in this article shall not apply to
the extent that (a) any receiving Party (“the Recipient”) is required (i) to disclose information by law, order or regulation of an administrative agency or a court of competent jurisdiction, or (ii) to disclose information to any
administrative agency for purposes of obtaining approval to manufacture, test or market a product, provided in either case that the Recipient shall provide written notice thereof to the other Party and sufficient opportunity to object, time
permitting, to any such disclosure or to request confidential treatment thereof; or (b) the Recipient can demonstrate that (i) the information was public knowledge, other than as a result disclosure to the Recipient by the other Party hereunder;
(iii) the information was disclosed to the Recipient on an unrestricted basis from a third party not under a duty of confidentiality to the other Party; or (iv) the information was independently developed by employees of the Recipient without access
to Confidential Information of the other Party. 
  
 Return Of Confidential
Information Upon Termination 
  
 6.3 Upon termination of this Agreement, each
Party shall promptly return to the other, at the other’s request, any and all Confidential Information of the other then in its possession or under its control except if such information is covered under surviving rights. 
  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 7 

 Article 7. DISPUTE RESOLUTION 
  
 Disputes 
  
 7.1 If at any time there is a dispute among the parties with respect to any matter relating to this Agreement, any party that wishes the issue to be considered further
will give notice to the other of that it requires the dispute to be decided under the terms of this Agreement. 
  
 Referral to Senior Officers 
  
 7.2
If a notice is given under §7.1, a senior officer designated by each party will undertake discussions for the purpose of settling the dispute. A decision reached by these officers and communicated in writing to the parties will be
determinative of the dispute and will be binding on each party. 
  
 Arbitration

  
 7.3 If no decision is reached under §7.2 within 30 days of the
dispute being sent for consideration, either party may, by notice to the other party given at any time before a decision is rendered under §7.2, submit the dispute (or determination by a single arbitrator acting under Hong Kong International
Arbitration Centre. 
  
 7.4 The arbitration will take place in Hong Kong and will
be administered by the Hong Kong International Arbitration Centre and conducted in accordance with the procedures of the centre. 
  
 Article 8. TERM AND TERMINATION 
  
 Term 
  
 8.1 This Agreement will be in effect for a ten-year period and will be renewed automatically for successive two-year terms unless other\vise terminated in accordance with the terms hereof (the “Term”).

  
 Termination by Either Party 
  
 8.2 Either party may terminate this Agreement 
  

	 	8.2.1 	upon notice given at least 180 days before the end of the current Term, such termination to come into effect at the end of that Term, or 

  

	 	8.2.2 	Immediately upon written notice if the other party 

  

	 	8.2.2.1 	is in breach or violates any of the terms and conditions of or fails to perform any of its obligations under this Agreement and, after receiving notice from the other party, does
not cure such default within 45 days, or 

	 	8.2.2.2 	becomes insolvent, bankrupt, makes an assignment for the benefit of its creditors or has a receiver, receiver/manager, trustee or liquidator appointed in respect of its business or
its assets. 

  
 Liabilities 
  
 8.3 Upon termination of this Agreement, Licensors will be required to complete any and all
existing Purchase Orders as at the date of termination and Agent or Licensees will be required to receive and pay for all Products shipped in connection with such Purchase Orders. 
  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 8 

 Article 9. LIABILITIES AND INDEMNIFICATION 
  
 Indeminification 
  
 9.1 Licensors will indemnify, hold harmless and defend Agent, its officers, employees, Licensees and agents against any all claims, suits, losses, damages, costs) fees,
and expenses resulting from or arising out of exercise of the rights granted under the definitive Agreement, the proper use of the Product or Finished Product and the sale of the Product or Finished Product under the label and indications. Zhongkai
will not be held responsible for the Product or Finished Product being used off label and out of the indications as specified in Schedule B or wrongly handled during transportation or storage at Agent’s or Licensees’ premises. Agent shall
ensure that Licensor is promptly notified of any such claims in which it intends to invoke this Article 9. Agent and its employees shall cooperate fully with Licensor and its legal representatives in the investigation and defense of any action)
claim or liability covered by this indemnification. 
  
 Insurance

  
 9.2 Licensors, at its sole cost and expense, will insure its activities
in connection with the work under this Agreement and obtain, keep in force, and maintain insurance or an equivalent program of self insurance. 
  
 Article 10. GENERAL PROVISIONS 
  
 Entire Agreement 
  
 10.1 This Agreement constitutes the entire agreement between the parties and supersedes every previous agreement, communication, negotiation, representation or understanding, whether oral or written, expressed or
implied, between the parties with respect to the subject matter of this Agreement. 
  
 10.2 No director, officer, employee or agent of any party has any authority to make any representation or commitment not contained in this Agreement and each party has executed this Agreement without reliance upon any such representation or
commitment. 
  
 Force Majeure 
  
 10.3 No party will be liable for its failure to perform any of its obligations under this
Agreement as a result of Acts of God (including all natural disasters), strikes, lockouts, civil disturbances, government or court ordered interruptions or delays, acts of war and riots, but that either Party to this Agreement may elect to terminate
it upon three months written notice to the other if force majeure cannot or is not remedied within three months after its occurrence. 
  
 Severability 
  
 10.4 If any provision of this Agreement is at any time unenforceable or invalid for any reason it will be severable from the remainder of this Agreement and this Agreement will be construed as though such provision
was not contained herein and the remainder will continue in full force and effect and be construed as if this Agreement had been executed without the invalid or unenforceable provision. 
  
 Amendments 
  
 10.5 This Agreement may not be amended except in writing signed by both parties. 
  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 9 

 Assignment 
  
 10.6 Neither party will be entitled to assign this Agreement without the written consent of the other party, which consent cannot be unreasonably withheld. 
  
 Governing Law 
  
 10.7 This Agreement is and will be deemed to have been made in Suzhou, China for all purposes will be governed exclusively by
and construed and enforced in accordance with the laws prevailing in Hong Kong and the rights and remedies of the parties will be determined in accordance with those laws. 
  
 Attornment 
  
 10.8 Each of the parties irrevocably attorns to the Hong Kong International Arbitration Center and all courts having appellate jurisdiction thereover. 

 
 Notice 
  
 10.9 To be effective, a notice, request, demand or direction (each for the purposes of this provision a “notice”) to be given
pursuant to this Agreement by one party to another party must be in writing and must be 
  

	 	10.9.1 	delivered by hand or by mail, or 

  

	 	10.9.2 	received by telecopy transmission or other similar form of written communication by electronic means, 

  
 in each case addressed as applicable as follows: 
  

If to Agent at: 
  
 East Asia Chambers 
 P.O. Box 901 

Road Town Tortola 
 British Virgin Island

 Attention: Mr. James Harris III or appointed person 
 Fax: + 1-604-669-4243 
  
 with a
copy to such other offices or Agent as may be specified by Agent to Licensors; 
  
 If to Licensors at: 
  
 Jiangsu
Wuzhong Industry Co. Ltd. 
 Suzhou Zhongkai Bio-Pharmaceuticals Plant 
 at 5, ChengHu Road, Wuzhong Economic Zone of Development. 
 SuZhou, People’s Republic of China.215128 
 Attention: Mr. Zhong Shenzheng or The person appointed

 Fax: +86-512w65620523 
  
 or to such other address or fax number as is specified by the addressee by notice to the other party. 
  
 10.10 A notice delivered or sent in accordance with §10.9 will be deemed to be given and received 
  

	 	10.10.1 	at 8.00 a.m. on the day of delivery or receipt at the place of delivery or receipt if that day is a Business Day at that place and the delivery or receipt is before that time on
that day) 

  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 10 

	 	10.10.2 	at the time of delivery or receipt if received on or after 8.00 a.m. and before 4.00 p.m. at the place of delivery or receipt on a day that is a Business Day at that place, and

  

	 	10.10.3 	at 8.00 a.m. at the place of delivery or receipt on the next day that is a Business Day at that place, if delivered or received on a day that is not a Business Day at that place or
at or after 4.00 p.m. at that place. 

  
 No Partnership

  
 10.11 Nothing in this Agreement will constitute, by any means, a
partnership between Licensors AND Agent or Licensees. 
  
 Binding Effect

  
 10.12 This Agreement will ensure to the benefit of and be binding upon
the respective successors and permitted assigns of the parties. 
  
 Further
Assurances 
  
 10.13 Each Party will carry out its corresponding
responsibilities and rights in order to execute this Agreement. For unforeseen expenses that may occur in the future, both Parties agree to negotiate in good faith. 
  
 Survival 
  
 10.14 The obligations under Section 6, 7, 8, 9 and 10 shall survive the termination of this Agreement. 
  
 Counterparts 
  
 10.15 This Agreement will be signed in English and Chinese, both of them should be identical and with the same effect. Should there appear differences of interpretation
then, the English version will supersede the Chinese version. 
  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 11 

 IN WITNESS WHEREOF this Agreement was executed by the parties as of the day and year first above writte!1. 
  

									
	 Allwin Biotrade, Inc.
	 	 	 	 Witnessed by:

					
	 Per:
	 	/s/    ALEXANDER WICK        	 	 	 	 Per:
	 	/s/    JAMES HARRIS        
			
	 Jiangsu Wuzhong Industry Co. Ltd.
	 	 	 	 Witnessed by:

					
	 Per:
	 	/s/    YAO JIANLIN        	 	 	 	 Per:
	 	/s/    ALAIN JANG        
			
	 Jiangsu Wuzhong Industry Co.,Ltd.
 Suzhou Zhongkai Bio-Pharmaceuticals Plant
	 	 	 	 Witnessed by:

					
	 Per:
	 	/s/    ZHONG SHENZHENG        	 	 	 	 Per:
	 	/s/    ALAIN JANG        

  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 12 

 SCHEDULE A 
  
 The following table lists out the price which will be in effect until one year after the date of first purchase order (FOB China) 
  

							
	 	 	 Vial Size

	 Number of Vials

	 	 75 ug

	 	 150 ug

	 	 300 ug

	 	 	USD	 	USD	 	USD
	      < 10,000
	 	* * *	 	* * *	 	* * *
	 10,001 - 50,000
	 	* * *	 	* * *	 	* * *
	 50,001 - 100,000
	 	* * *	 	* * *	 	* * *
	 10,001 - 200,000
	 	* * *	 	* * *	 	* * *
	      > 200,000
	 	* * *	 	* * *	 	* * *

  
 * * * CONFIDENTIAL
MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 
  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 13 

 SCHEDULE B 
  

Product: JIEXIN 
  
 Granulocyte Colony Stimulating Factor (“GCSF”) for injection. 
  
 Market Area: 
  
 REGION - Africa. 
  
 COUNTRY

  
 Angola, Benin, Burkina Fasco, Cameroon, Central African, Chad, Cobo
Verde, Congo, Ethiopia, Gabon, Ghana, Guinea Conakry, Guinea-Bissau, Ivory-Coast, Kenya, Madagascar, Mali, Mauritania, Mozambique, Namibia. Nigeria. S. Tome and Principe, Senegal, South Africa, Sudan, Tanzania, Togo, Uganda, Zaire, Zambia, Zimbabwe

  
 REGION -Asia. 
  
 COUNTRY 
  
 Bangladesh, Brune, Burma. East Timor; India, Indonesia, Laos, Malaysia, Mauritius, Myanmar, North Korea, Pakistan, Philippines, Singapore,
South Korea, Sri Lanka. Taiwan, Thailand 
  
 REGION -Eastern Europe

  
 COUNTRY 
  
 Albania, Armenia, Azerbaijan, Bulgaria, Byelorussia, Croatia, Czech Republic, Estonia, Georgia, Hungary, Kazakhstan, Kirgizstan, Kosovo,
Latvia, Lithuania. Macedonia. Moldova, Monogolia, Poland, Romania. Russia, Serbia, Slovakia, Slovenia, Ukraine, Uzbekistan 
  
 REGION -Western Europe 
  
 COUNTRY 
  
 Austria, Belgium, Denmark,
Finland, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, Malta, Netherlands. Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom 
  
 REGION -Latin America 
  
 COUNTRY 
  
 Argentina, Aruba, Barbados,
Belize, Bolivia, Brazil, Chile, Colombia, Costa. Rica., Cuba, Dominican Republic, Ecuador, EI Salvador, French Guyana, Guatemala, Guyana, Haiti, Honduras, Jamaica, Martinique, Mexico, Nicaragua, Panama, Paraguay, Peru, Salvador, Surinam,
Trinidad-Tobago, Uruguay, Venezuela 
  
 REGION -Middle East & North
Africa 
  
 COUNTRY 
  
 Algeria, Egypt, Eritrea, Gulf States, Iran, Iraq, Jordan, Lebanon, Libya, Morocco, Oman,
Palestine, Syria, Tunisia, Turkey, Yemen 
  
 REGION -North America

  
 COUNTRY 
  
 Canada, United States 
  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 14 

 REGION -South Pacific 
  
 COUNTRY 
  
 Australia, New Zealand 
  
 *Remark: Supposed there
is no any sales results happened in the above listed regions and countries within 3 years after signing the agreement, then these areas will not be included. 
  
 Indications: 
  
 Cancer Patients Receiving Myelosuppressive Chemotherapy 
  
 GCSF is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patient with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant
incidence of severe neutropenia with fever. 
  
 Patients With Acute Myeloid
Leukemia Receiving Induction or Consolidation Chemotherapy 
  
 GCSF is
indicated for reducing the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment of adults with AML. 
  

Cancer Patients Receiving Bone Marrow Transplant 
  
 GCSF is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g. febrile: neutropenia, in patients with nonmyeloid malignancies
undergoing myeloablative chemotherapy followed by marrow transplantation. 
  
 Patient Undergoing Peripheral Bood Progenitor Cell Collection and Therapy 
  
 GSCF is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. 
  
 Patients With Severe Chronic Neutropenia 
  
 GSCF is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g. fever, infections; oropharyngeal ulcers) in symptomatic
patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia. 
  
 Also, and any other indications approved in the Market Area at the time of Product Approval or subsequently thereafter. 
  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 15 

 SCHEDULE C 
  

Costs and Responsibilities: 
  

					
	 Description

	 	 Responsibility

	 	 Payments

	Manufacturing and analysis of Product or Finished Product (rhG-CSF)	 	Licensors	 	Licensors*
			
	Preparation of shipment, packaging	 	Licensors	 	Licensors*
			
	Shipment using air-mail	 	Licensors	 	Licensors or Agent and Licensees *
			
	Preparation of Customs documents	 	Licensors	 	Licensors*
			
	Customs clearance in China	 	Licensors	 	Licensors.
			
	Customs clearance in Arrival Airport	 	Licensees	 	Licensees
			
	Receipt from custom-house	 	Licensees	 	Licensees
			
	Quality analysis of the product in company, Licensor should receive the analysis report within 20 business days, otherwise, the products were deemed to be qualified.	 	Agent or Licensees	 	Agent or Licensees
			
	Analysis in independent laboratory in the case of quality not complying with requirements and payments connected with such an analysis	 	Agent or Licensees	 	If, in opinion of the independent laboratory, the quality is good - Agent. if not - Licensors
			
	Checking analysis in another laboratory	 	Licensors	 	Licensors
			
	Packaging and labeling	 	Licensees	 	Licensees
			
	Sales and distribution	 	Agent or Licensees	 	Agent or Licensees

  

	*-	Included in the price of the Product. 

  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 16 

 SCHEDULE D 
  

Licensors Documentation Expenses 
  
 Licensors will be billed at a price of USD$* * *. 
  
 * * * CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 
  

 Initial: /s/ Zhong /s/ AW 
 CONFIDENTIAL INFORMATION 
  
 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}]]